Zhejiang Shengda Bio-Pharm Co., Ltd. (SHA:603079)
China · Delayed Price · Currency is CNY 20.16
-0.08 (-0.40%)
Feb 4, 2026, 3:00 PM CST
SHA:603079 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 839.03 | 826.61 | 725.46 | 736.96 | 788.5 | 860.26 |
Other Revenue | 0.79 | 0.79 | 1.94 | 1.06 | 1.23 | 7.06 |
| 839.82 | 827.4 | 727.41 | 738.02 | 789.73 | 867.31 | |
Revenue Growth (YoY) | 6.02% | 13.75% | -1.44% | -6.55% | -8.95% | 67.06% |
Cost of Revenue | 637.43 | 663.8 | 653.22 | 627.75 | 573.41 | 412.22 |
Gross Profit | 202.39 | 163.6 | 74.18 | 110.27 | 216.33 | 455.09 |
Selling, General & Admin | 74.04 | 76.78 | 74.1 | 73.84 | 104.28 | 145.92 |
Research & Development | 50.31 | 43.76 | 42.92 | 37.42 | 39.64 | 35.69 |
Other Operating Expenses | 5.62 | 6.05 | 8.47 | 8.63 | 11.02 | 12.25 |
Operating Expenses | 129.34 | 132.06 | 128.66 | 120.34 | 155.84 | 193.47 |
Operating Income | 73.05 | 31.54 | -54.48 | -10.07 | 60.49 | 261.62 |
Interest Expense | -1.84 | -2.08 | -1.54 | -4.56 | -5.76 | -4.64 |
Interest & Investment Income | 9.27 | 8.67 | 8.81 | 15.28 | 24.47 | 5.5 |
Currency Exchange Gain (Loss) | 4.1 | 4.1 | 3.86 | 22.76 | -5.27 | -21.69 |
Other Non Operating Income (Expenses) | -9.45 | -0.21 | -0.3 | -0.3 | -0.77 | -0.32 |
EBT Excluding Unusual Items | 75.13 | 42.02 | -43.63 | 23.11 | 73.16 | 240.47 |
Gain (Loss) on Sale of Investments | -0 | 0 | 0 | -0.9 | 0.01 | - |
Gain (Loss) on Sale of Assets | 0.02 | 0.15 | 0.2 | 0.09 | 0 | -0.01 |
Asset Writedown | 3.76 | -0.29 | -12.21 | -0.1 | -1.52 | -1.02 |
Legal Settlements | -8.1 | -8.1 | - | - | - | - |
Other Unusual Items | 15.17 | 15.31 | 10.33 | 14.32 | 8.39 | -15.76 |
Pretax Income | 85.98 | 49.09 | -45.31 | 36.52 | 80.04 | 223.67 |
Income Tax Expense | 17.4 | 11.83 | 8.89 | 6.09 | 8.22 | 33.7 |
Earnings From Continuing Operations | 68.58 | 37.26 | -54.2 | 30.44 | 71.82 | 189.97 |
Minority Interest in Earnings | -7.49 | -7.83 | 0.14 | 1.05 | 3.93 | 7.47 |
Net Income | 61.08 | 29.42 | -54.06 | 31.48 | 75.76 | 197.44 |
Net Income to Common | 61.08 | 29.42 | -54.06 | 31.48 | 75.76 | 197.44 |
Net Income Growth | - | - | - | -58.44% | -61.63% | 319.81% |
Shares Outstanding (Basic) | 181 | 173 | 169 | 175 | 172 | 169 |
Shares Outstanding (Diluted) | 181 | 173 | 169 | 175 | 172 | 169 |
Shares Change (YoY) | 16.46% | 2.45% | -3.41% | 1.59% | 2.03% | 7.64% |
EPS (Basic) | 0.34 | 0.17 | -0.32 | 0.18 | 0.44 | 1.17 |
EPS (Diluted) | 0.34 | 0.17 | -0.32 | 0.18 | 0.44 | 1.17 |
EPS Growth | - | - | - | -59.09% | -62.39% | 290.00% |
Free Cash Flow | -10.36 | -21.97 | -181.51 | -22.54 | -25.5 | 248.05 |
Free Cash Flow Per Share | -0.06 | -0.13 | -1.07 | -0.13 | -0.15 | 1.47 |
Dividend Per Share | - | - | 0.060 | 0.060 | 0.140 | 0.350 |
Dividend Growth | - | - | - | -57.14% | -60.00% | 308.40% |
Gross Margin | 24.10% | 19.77% | 10.20% | 14.94% | 27.39% | 52.47% |
Operating Margin | 8.70% | 3.81% | -7.49% | -1.36% | 7.66% | 30.16% |
Profit Margin | 7.27% | 3.56% | -7.43% | 4.27% | 9.59% | 22.76% |
Free Cash Flow Margin | -1.23% | -2.66% | -24.95% | -3.05% | -3.23% | 28.60% |
EBITDA | 148.06 | 105.28 | 17.58 | 57.63 | 131.39 | 331.34 |
EBITDA Margin | 17.63% | 12.72% | 2.42% | 7.81% | 16.64% | 38.20% |
D&A For EBITDA | 75 | 73.74 | 72.06 | 67.69 | 70.9 | 69.72 |
EBIT | 73.05 | 31.54 | -54.48 | -10.07 | 60.49 | 261.62 |
EBIT Margin | 8.70% | 3.81% | -7.49% | -1.36% | 7.66% | 30.16% |
Effective Tax Rate | 20.24% | 24.10% | - | 16.66% | 10.27% | 15.07% |
Revenue as Reported | 839.82 | 827.4 | 727.41 | 738.02 | 789.73 | 867.31 |
Advertising Expenses | - | 2.04 | 1.27 | 0.65 | 0.37 | 0.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.